82718-15-8

Basic information

• Product Name: 1H-Benzimidazole,5-(4-pyridinyl)-(9CI)
• Synonyms: 1H-Benzimidazole,5-(4-pyridinyl)-(9CI);6-(4-pyridinyl)-1H-Benzimidazole
• CAS NO: 82718-15-8
• Molecular Formula: C12H9N3
• Molecular Weight: 195.21996
• Product Categories: BENZIMIDAZOLE
• Mol File: 82718-15-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 487.2±20.0 °C(Predicted)
• Appearance: /
• Density: 1.270±0.06 g/cm3(Predicted)
• PKA: 11.65±0.10(Predicted)
• CAS DataBase Reference: 1H-Benzimidazole,5-(4-pyridinyl)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole,5-(4-pyridinyl)-(9CI)(82718-15-8)
• EPA Substance Registry System: 1H-Benzimidazole,5-(4-pyridinyl)-(9CI)(82718-15-8)

Safety Data

• Hazardous Substances Data: 82718-15-8(Hazardous Substances Data)

Usage

Type of compound

heterocyclic (contains a benzimidazole ring fused with a pyridine ring)

Applications

pharmaceuticals, agrochemicals, building block in organic synthesis

Pharmacological properties

potential anti-cancer, anti-inflammatory, and anti-microbial activity

Use as a ligand

in coordination chemistry, forms coordination complexes with various metal ions

Ongoing research

for potential uses in various fields

Upstream product

• 80420-88-8 4-(pyridin-4-yl)benzene-1,2-diamine 
• 122-51-0 orthoformic acid triethyl ester 
• 59656-62-1 4-(4-amino-3-nitrophenyl)-pyridine 
• 149-73-5 trimethyl orthoformate 

Relevant articles and documents

Src kinase inhibitor compounds

Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.

5-(Pyridinyl)-1H-benzimidazoles and 1-hydroxy-6-(pyridinyl)-1H-benzimidazoles and their cardiotonic use

2-R-5-(Py-Y)-1H-benzimidazole or pharmaceutically-acceptable acid-addition salt thereof, useful as a cardiotonic, is prepared by reacting 4-(Py-Y)-1,2-benzenediamine with a tri-(lower-alkyl)ortho-(lower-alkanoate) of the formula R--C(OR1)3